Endosense SA is a medical device company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias.
Granted the CE mark in May 2009, Endosense SA’s TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.
TactiCath® has undergone considerable preclinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
In August 2013 Endosense SA was acquired for total cash considerations of up to CHF309 million (USD331 million) by St. Jude Medical, Inc., a global medical device company (NYSE:STJ).
Granted the CE mark in May 2009, Endosense SA’s TactiCath® is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.
TactiCath® has undergone considerable preclinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.
In August 2013 Endosense SA was acquired for total cash considerations of up to CHF309 million (USD331 million) by St. Jude Medical, Inc., a global medical device company (NYSE:STJ).
Location: Switzerland
Total raised: $105.54M
Investors 2
| Date | Name | Website |
| - | NeoMed Man... | neomed.net... |
| - | GIMV | gimv.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 27.11.2013 | Series C | $41.19M | - |
| 05.03.2013 | Series C | $4.3M | - |
| 27.11.2012 | Series C | $40.3M | - |
| 21.11.2005 | - | $19.75M | NeoMed Man... |
Mentions in press and media 21
| Date | Title | Description |
| 27.11.2013 | Endosense closes CHF 37.4 million series C round | |
| 20.08.2013 | St. Jude Medical Acquires Endosense | St. Jude Medical (NYSE: STJ), a St.Paul, Minnesota-based a global medical device company, acquired Endosense, a Geneva, Switzerland-based medical technology company focused on treating cardiac arrhythmias. St. Jude Medical will initially pa... |
| 19.08.2013 | St. Jude Medical acquires Endosense for up to CHF309 million | |
| 15.05.2013 | HRS13: Endosense’s force-sensing ablation catheter | Geneva-based Endosense’s proprietary contact force technology improves efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, according to new study data released last week at the annual Heart Rhythm Society meet... |
| 06.03.2013 | Endosense Secures Additional $4.3M in Series C Financing | Endosense, a Geneva, Switzerland-based medical technology company, secured an additional USD$4.3m (CHF4m) in Series C financing. The backer was a new unnamed strategic industry partner. This second closing brings the total in series C funds... |
| 05.03.2013 | Endosense raises additional CHF 4m | |
| 05.03.2013 | Endosense closes an additional USD 4.3 Million/CHF 4 Million in Series C Financing | Endosense, a pioneer and leader in contact-force sensing technology focused on improving the efficacy and safety of catheter ablation for the treatment of cardiac arrhythmias, announced today that it has secured an additional USD 4.3 millio... |
| 05.03.2013 | Endosense Closes an Additional $4.3M | GENEVA, SWITZERLAND, Pioneer and leader in contact-force sensing technology announced today that it has secured an additional USD 4.3 million/CHF 4 million in Series C financing. >> Click here for more funding data on Endosense &g... |
| 06.02.2013 | First U.S. Case Performed with Endosenses Ablation Catheter | |
| 12.12.2012 | Endosense hires former Merck Sereno manager as CFO |
Show more